Welcome to our dedicated page for EUPRAXIA PHARMACEUTICALS SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EUPRAXIA PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EUPRAXIA PHARMACEUTICALS's regulatory disclosures and financial reporting.
Eupraxia Pharmaceuticals Inc. is offering securities under a shelf prospectus of up to US$200,000,000 in one or more series, including common shares, preferred shares, debt, warrants, subscription receipts and units. The prospectus supplement discusses two lead product candidates: EP-104IAR (intra-articular injections for knee osteoarthritis; completed a Phase 2 study) and EP-104GI (submucosal injections for eosinophilic esophagitis; open-label Phase 1b/2a RESOLVE trial ongoing). The company received pre-IND/FDA feedback and reached agreement with FDA on late-phase requirements for EP-104IAR and program requirements for EP-104GI. The filing notes material risks: significant additional funding will be required, development and regulatory approval are uncertain, clinical CRO performance and manufacturing/GMP compliance are necessary, potential dilution from existing warrants/options/convertible securities (including 8,905,638 Series 1 Preferred Shares at C$5.00) and loss of foreign private issuer status could increase U.S. compliance costs. The company may seek partners for development and plans to allocate proceeds to clinical development, R&D, manufacturing scale-up and general corporate purposes.
EUPRAXIA PHARMACEUTICALS INC. submitted a Form 6-K reporting its principal executive office address in Victoria, British Columbia, and indicated it files annual reports under Form 40-F. The report includes an exhibit: Exhibit 99.1, a press release dated September 22, 2025. The document is signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025. The filing appears to be a routine disclosure providing company contact details, the chosen annual-reporting form and a referenced press release.